Navigation Links
Older and younger chronic leukemia patients may need different therapy
Date:12/12/2012

  • People who develop chronic lymphocytic leukemia (CLL) are typically age 65 and older, but participants in CLL clinical trials are usually several years younger;
  • The age of CLL patients is not usually considered when determining treatment;
  • This study suggests that older and younger CLL patients require different therapy.

COLUMBUS, Ohio Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

Age is usually not considered when determining treatment for people with CLL, but this study indicates that older people with CLL may not respond as well to the therapy used for most patients.

The study was published Dec. 10 in the Journal of Clinical Oncology.

"Our analysis shows that optimal therapy for younger and older patients with chronic lymphocytic leukemia is likely to be different, at least when using current treatments," says first author Dr. Jennifer Woyach, assistant professor of hematology at the OSUCCC James.

"We hope this study will shape future research by highlighting the importance of enrolling older patients on clinical trials and of developing trials that specifically target older patients."

Doctors diagnose about 15,000 new cases of chronic lymphocytic leukemia (CLL) annually in the United States, making it the most common form of leukemia. It remains incurable, and about 4,400 Americans die of the malignancy each year. CLL most often occurs in people older than age 65; the average age at diagnosis is 72. Yet, most

CLL clinical-trial participants are in their early 60s.

"Our findings apply to both routine care of CLL patients 70 years and older and to future CLL trials," says principal investigator Dr. John Byrd, a CLL specialist and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC James.

"The study suggests that chlorambucil is superior to fludarabine in older patients, and that CD20 antibody therapies such as rituximab are beneficial as front-line therapy for all CLL patients, regardless of age," says Byrd, who is the D. Warren Brown Designated Chair in Leukemia Research.

"These data also show that future treatment trials for older adults with CLL should build on CD20 antibody therapies such as rituximab and ofatumumab, but not on fludarabine or alemtuzumab."

Byrd, Woyach and their colleagues reviewed 663 CLL patients who were enrolled in four sequential CLL clinical trials evaluating front-line therapies. The researchers looked for differences in treatment outcomes between older and younger patients to identify the most effective therapy for older adults.

The four trials, all sponsored by the Cancer and Leukemia Group B (CALGB) clinical cooperative group, compared these treatments: chlorambucil versus fludarabine, fludarabine plus rituximab versus fludarabine, fludarabine with consolidation alemtuzumab, and fludarabine plus rituximab with consolidation alemtuzumab.

Key conclusions include:

  • Fludarabine versus chlorambucil: Fludarabine improved progression-free survival and overall survival among patients younger than age 70 but chlorambucil tended to produce higher overall survival in patients older than 70.
  • Rituximab combined with fludarabine, versus fludarabine alone, improves progression-free and overall survival in both younger and older patients.
  • Alemtuzumab consolidation therapy after chemotherapy or chemoimmunotherapy does not improve progression-free or overall survival in either younger or older patients.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Fear of falling may cause social isolation in older adults with vision problems
2. Maintaining weight loss as important as losing it for older women
3. Reduced intensity regimen prior to marrow transplant better for older leukemia patients
4. Paradox of aging: The older we get, the better we feel?
5. RI Hospital: Standardized road test results differ from older adults natural driving
6. Findings support safety of whooping cough vaccine for older adults
7. Long-Term Use of Some Antipsychotics Not Warranted in Older Adults: Study
8. Carbon Monoxide Poisoning Hazards Rise in Colder Weather
9. Heart failure in older breast cancer patients linked to medication
10. Smart drug improves survival in older patients with acute myeloid leukemia
11. Hip Surgery Increases Stroke Risk in Older Patients: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... , ... W.S. Badger Co. Inc ., the maker of certified organic ... Works Award for its use of effective workplace strategies to increase business and employee ... by the Families and Work Institute (FWI) and the Society for Human Resource Management ...
(Date:5/26/2016)... Louis, Missouri (PRWEB) , ... May 26, 2016 ... ... cost, quality and clinical outcomes, hosted members and suppliers for its inaugural Member ... a focus on their mission of elevating the operational health of America’s healthcare ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John Knox Village , ... of care for living and healing, celebrated its grand opening, today. The Woodlands at ... Home provided by Empowered Staff. , “This is an incredibly fulfilling time for John ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 ... 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world ... Cancer Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... According to a new market report ... U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 ... was valued at US$ 5.89 Bn in 2014 and is ... to 2023 to reach US$ 7.99 Bn in 2023. ... needle free drug delivery devices and the market is estimated ...
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... 2016 According to a new ... 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by ... Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", published ... Market for the forecast period of 2016 to 2021. ... by 2021 from USD 117.3 Million in 2016, at ...
Breaking Medicine Technology: